Phreesia (NYSE:PHR) Price Target Raised to $34.00 at Robert W. Baird

Phreesia (NYSE:PHR) had its price objective increased by Robert W. Baird from $31.00 to $34.00 in a report released on Friday, Benzinga reports. They currently have an outperform rating on the stock.

PHR has been the topic of a number of other research reports. Stephens reiterated an overweight rating and set a $28.00 price target on shares of Phreesia in a report on Friday, May 31st. Canaccord Genuity Group reissued a buy rating and issued a $34.00 target price on shares of Phreesia in a report on Thursday. DA Davidson reaffirmed a buy rating and set a $32.00 price objective on shares of Phreesia in a research report on Thursday. Needham & Company LLC reissued a buy rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday. Finally, JMP Securities reaffirmed a market outperform rating and set a $30.00 price target on shares of Phreesia in a report on Thursday. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $30.92.

Phreesia Price Performance

Shares of NYSE:PHR opened at $23.55 on Friday. The company has a market capitalization of $1.35 billion, a PE ratio of -10.85 and a beta of 0.93. The business has a fifty day moving average price of $23.38 and a 200-day moving average price of $22.79. Phreesia has a 1-year low of $12.05 and a 1-year high of $29.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76.

Insider Activity at Phreesia

In related news, General Counsel Allison C. Hoffman sold 14,110 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the sale, the general counsel now directly owns 121,003 shares of the company’s stock, valued at approximately $3,149,708.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Chaim Indig sold 2,644 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $62,768.56. Following the completion of the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $26.03, for a total transaction of $367,283.30. Following the completion of the sale, the general counsel now owns 121,003 shares in the company, valued at approximately $3,149,708.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,337 shares of company stock worth $736,750. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC lifted its holdings in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after acquiring an additional 1,300 shares during the last quarter. Russell Investments Group Ltd. raised its position in Phreesia by 5,462.3% in the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after purchasing an additional 3,769 shares during the period. EntryPoint Capital LLC bought a new stake in Phreesia in the first quarter worth about $169,000. Quadrature Capital Ltd purchased a new position in shares of Phreesia during the first quarter valued at approximately $202,000. Finally, Lombard Odier Asset Management USA Corp bought a new position in shares of Phreesia during the second quarter valued at approximately $202,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.